The Experts below are selected from a list of 6210 Experts worldwide ranked by ideXlab platform

Pavel Tichy - One of the best experts on this subject based on the ideXlab platform.

  • plan commit Execute Protocol in multi agent systems
    International Conference on Industrial Applications of Holonic and Multi-Agent Systems, 2009
    Co-Authors: Petr Kadera, Pavel Tichy
    Abstract:

    In this paper we introduce changes made in Plan/Commit/Execute negotiation Protocol originally developed for Agent Cooperation System and practically used in Chilled Water System application. This Protocol is suitable for systems where the commitment of resources and execution of a plan require separated communication phases. The extension of the Protocol with Reject Proposal message that is used for canceling unsatisfactory proposals is the most significant change. We also describe the deployment of the Protocol in new version of Multi-agent System for Manufacturing.

  • HoloMAS - Plan, Commit, Execute Protocol in Multi-agent Systems
    Holonic and Multi-Agent Systems for Manufacturing, 2009
    Co-Authors: Petr Kadera, Pavel Tichy
    Abstract:

    In this paper we introduce changes made in Plan/Commit/Execute negotiation Protocol originally developed for Agent Cooperation System and practically used in Chilled Water System application. This Protocol is suitable for systems where the commitment of resources and execution of a plan require separated communication phases. The extension of the Protocol with Reject Proposal message that is used for canceling unsatisfactory proposals is the most significant change. We also describe the deployment of the Protocol in new version of Multi-agent System for Manufacturing.

Petr Kadera - One of the best experts on this subject based on the ideXlab platform.

  • plan commit Execute Protocol in multi agent systems
    International Conference on Industrial Applications of Holonic and Multi-Agent Systems, 2009
    Co-Authors: Petr Kadera, Pavel Tichy
    Abstract:

    In this paper we introduce changes made in Plan/Commit/Execute negotiation Protocol originally developed for Agent Cooperation System and practically used in Chilled Water System application. This Protocol is suitable for systems where the commitment of resources and execution of a plan require separated communication phases. The extension of the Protocol with Reject Proposal message that is used for canceling unsatisfactory proposals is the most significant change. We also describe the deployment of the Protocol in new version of Multi-agent System for Manufacturing.

  • HoloMAS - Plan, Commit, Execute Protocol in Multi-agent Systems
    Holonic and Multi-Agent Systems for Manufacturing, 2009
    Co-Authors: Petr Kadera, Pavel Tichy
    Abstract:

    In this paper we introduce changes made in Plan/Commit/Execute negotiation Protocol originally developed for Agent Cooperation System and practically used in Chilled Water System application. This Protocol is suitable for systems where the commitment of resources and execution of a plan require separated communication phases. The extension of the Protocol with Reject Proposal message that is used for canceling unsatisfactory proposals is the most significant change. We also describe the deployment of the Protocol in new version of Multi-agent System for Manufacturing.

Kenneth I. Kaitin - One of the best experts on this subject based on the ideXlab platform.

  • Variability in Protocol Design Complexity by Phase and Therapeutic Area
    Drug Information Journal, 2011
    Co-Authors: Kenneth A. Getz, Rafael A. Campo, Kenneth I. Kaitin
    Abstract:

    The Tufts Center for the Study of Drug Development analyzed 8,317 clinical trial Protocols to benchmark Protocol complexity by phase and therapeutic area and to characterize trends in clinical trial complexity and the burden placed on study staff to Execute Protocol procedures between 2000 and 2007. Wide variability in Protocol complexity and work burden was observed across therapeutic areas, within and between clinical research phases. Phase 1 Protocols are the most complex and the most demanding to Execute. The mean number of total procedures per Protocol in phase 4 studies and the work burden associated with phase 1 Protocols grew the fastest between the periods 2000-2003 and 2004–2007. The complexity and work burden of phase 3 Protocols also grew rapidly during this period. Protocols in anti-infectives, immunomodulation, CNS, and oncology are consistently the most complex and burdensome to Execute. Reasons for the wide variability in Protocol complexity and work burden by phase and therapeutic area ar...

  • Variability in Protocol Design Complexity by Phase and Therapeutic Area
    Drug information journal : DIJ Drug Information Association, 2011
    Co-Authors: Kenneth A. Getz, Rafael A. Campo, Kenneth I. Kaitin
    Abstract:

    The Tufts Center for the Study of Drug Development analyzed 8,317 clinical trial Protocols to benchmark Protocol complexity by phase and therapeutic area and to characterize trends in clinical trial complexity and the burden placed on study staff to Execute Protocol procedures between 2000 and 2007. Wide variability in Protocol complexity and work burden was observed across therapeutic areas, within and between clinical research phases. Phase 1 Protocols are the most complex and the most demanding to Execute. The mean number of total procedures per Protocol in phase 4 studies and the work burden associated with phase 1 Protocols grew the fastest between the periods 2000-2003 and 2004–2007. The complexity and work burden of phase 3 Protocols also grew rapidly during this period. Protocols in anti-infectives, immunomodulation, CNS, and oncology are consistently the most complex and burdensome to Execute. Reasons for the wide variability in Protocol complexity and work burden by phase and therapeutic area are discussed. This study provides insight into areas where Protocol design improvements should be targeted.

Kenneth A. Getz - One of the best experts on this subject based on the ideXlab platform.

  • Variability in Protocol Design Complexity by Phase and Therapeutic Area
    Drug Information Journal, 2011
    Co-Authors: Kenneth A. Getz, Rafael A. Campo, Kenneth I. Kaitin
    Abstract:

    The Tufts Center for the Study of Drug Development analyzed 8,317 clinical trial Protocols to benchmark Protocol complexity by phase and therapeutic area and to characterize trends in clinical trial complexity and the burden placed on study staff to Execute Protocol procedures between 2000 and 2007. Wide variability in Protocol complexity and work burden was observed across therapeutic areas, within and between clinical research phases. Phase 1 Protocols are the most complex and the most demanding to Execute. The mean number of total procedures per Protocol in phase 4 studies and the work burden associated with phase 1 Protocols grew the fastest between the periods 2000-2003 and 2004–2007. The complexity and work burden of phase 3 Protocols also grew rapidly during this period. Protocols in anti-infectives, immunomodulation, CNS, and oncology are consistently the most complex and burdensome to Execute. Reasons for the wide variability in Protocol complexity and work burden by phase and therapeutic area ar...

  • Variability in Protocol Design Complexity by Phase and Therapeutic Area
    Drug information journal : DIJ Drug Information Association, 2011
    Co-Authors: Kenneth A. Getz, Rafael A. Campo, Kenneth I. Kaitin
    Abstract:

    The Tufts Center for the Study of Drug Development analyzed 8,317 clinical trial Protocols to benchmark Protocol complexity by phase and therapeutic area and to characterize trends in clinical trial complexity and the burden placed on study staff to Execute Protocol procedures between 2000 and 2007. Wide variability in Protocol complexity and work burden was observed across therapeutic areas, within and between clinical research phases. Phase 1 Protocols are the most complex and the most demanding to Execute. The mean number of total procedures per Protocol in phase 4 studies and the work burden associated with phase 1 Protocols grew the fastest between the periods 2000-2003 and 2004–2007. The complexity and work burden of phase 3 Protocols also grew rapidly during this period. Protocols in anti-infectives, immunomodulation, CNS, and oncology are consistently the most complex and burdensome to Execute. Reasons for the wide variability in Protocol complexity and work burden by phase and therapeutic area are discussed. This study provides insight into areas where Protocol design improvements should be targeted.

Rafael A. Campo - One of the best experts on this subject based on the ideXlab platform.

  • Variability in Protocol Design Complexity by Phase and Therapeutic Area
    Drug Information Journal, 2011
    Co-Authors: Kenneth A. Getz, Rafael A. Campo, Kenneth I. Kaitin
    Abstract:

    The Tufts Center for the Study of Drug Development analyzed 8,317 clinical trial Protocols to benchmark Protocol complexity by phase and therapeutic area and to characterize trends in clinical trial complexity and the burden placed on study staff to Execute Protocol procedures between 2000 and 2007. Wide variability in Protocol complexity and work burden was observed across therapeutic areas, within and between clinical research phases. Phase 1 Protocols are the most complex and the most demanding to Execute. The mean number of total procedures per Protocol in phase 4 studies and the work burden associated with phase 1 Protocols grew the fastest between the periods 2000-2003 and 2004–2007. The complexity and work burden of phase 3 Protocols also grew rapidly during this period. Protocols in anti-infectives, immunomodulation, CNS, and oncology are consistently the most complex and burdensome to Execute. Reasons for the wide variability in Protocol complexity and work burden by phase and therapeutic area ar...

  • Variability in Protocol Design Complexity by Phase and Therapeutic Area
    Drug information journal : DIJ Drug Information Association, 2011
    Co-Authors: Kenneth A. Getz, Rafael A. Campo, Kenneth I. Kaitin
    Abstract:

    The Tufts Center for the Study of Drug Development analyzed 8,317 clinical trial Protocols to benchmark Protocol complexity by phase and therapeutic area and to characterize trends in clinical trial complexity and the burden placed on study staff to Execute Protocol procedures between 2000 and 2007. Wide variability in Protocol complexity and work burden was observed across therapeutic areas, within and between clinical research phases. Phase 1 Protocols are the most complex and the most demanding to Execute. The mean number of total procedures per Protocol in phase 4 studies and the work burden associated with phase 1 Protocols grew the fastest between the periods 2000-2003 and 2004–2007. The complexity and work burden of phase 3 Protocols also grew rapidly during this period. Protocols in anti-infectives, immunomodulation, CNS, and oncology are consistently the most complex and burdensome to Execute. Reasons for the wide variability in Protocol complexity and work burden by phase and therapeutic area are discussed. This study provides insight into areas where Protocol design improvements should be targeted.